Daito Pharmaceutical Co.,Ltd.
TSE:4577.T
2218 (JPY) • At close September 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) JPY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 46,895 | 45,101 | 43,464 | 48,709.171 | 44,997.108 | 41,135.053 | 39,883.625 | 37,973.361 | 36,331.198 | 34,062.366 | 31,202.24 | 28,959.211 | 27,149.438 | 25,218.38 | 22,679.543 | 21,460.675 |
| Cost of Revenue
| 37,056 | 34,770 | 32,005 | 37,917.256 | 35,512.638 | 32,463.335 | 31,765.385 | 30,232.301 | 29,104.413 | 26,990.4 | 25,213.09 | 23,031.113 | 21,491.131 | 20,518.157 | 18,982.936 | 17,937.1 |
| Gross Profit
| 9,839 | 10,331 | 11,459 | 10,791.915 | 9,484.47 | 8,671.718 | 8,118.24 | 7,741.06 | 7,226.785 | 7,071.966 | 5,989.15 | 5,928.098 | 5,658.307 | 4,700.223 | 3,696.607 | 3,523.575 |
| Gross Profit Ratio
| 0.21 | 0.229 | 0.264 | 0.222 | 0.211 | 0.211 | 0.204 | 0.204 | 0.199 | 0.208 | 0.192 | 0.205 | 0.208 | 0.186 | 0.163 | 0.164 |
| Reseach & Development Expenses
| 2,349 | 1,865 | 1,749 | 2,032 | 1,400 | 1,608 | 1,522.562 | 1,266.588 | 1,174.143 | 1,182 | 890 | 1,113 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3,050.213 | 3,249.21 | 3,031.741 | 2,741.356 | 2,245.676 | 2,185.084 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 5,945 | 3,078 | 2,990 | 2,712 | 2,609 | 2,394 | 2,300.219 | 2,393.373 | 2,348.44 | 2,243 | 3,050.213 | 3,249.21 | 3,031.741 | 2,741.356 | 2,245.676 | 2,185.084 |
| Other Expenses
| 2 | 3 | 37 | 28.406 | 28.762 | 28.293 | 25.824 | 47.925 | 42.738 | 40.039 | 30.015 | 25.893 | 97.596 | 80.433 | 22.999 | 51.982 |
| Operating Expenses
| 5,945 | 5,123 | 4,905 | 4,883.086 | 4,127.157 | 4,124.401 | 3,957.083 | 3,908.893 | 3,670.937 | 3,552.994 | 3,050.213 | 3,249.21 | 3,031.741 | 2,741.356 | 2,245.676 | 2,185.084 |
| Operating Income
| 3,894 | 5,207 | 6,553 | 5,908.827 | 5,357.313 | 4,547.317 | 4,161.156 | 3,832.165 | 3,555.847 | 3,518.971 | 2,938.938 | 2,678.887 | 2,626.565 | 1,958.864 | 1,450.93 | 1,338.489 |
| Operating Income Ratio
| 0.083 | 0.115 | 0.151 | 0.121 | 0.119 | 0.111 | 0.104 | 0.101 | 0.098 | 0.103 | 0.094 | 0.093 | 0.097 | 0.078 | 0.064 | 0.062 |
| Total Other Income Expenses Net
| 324 | -135 | 152 | -43 | 233 | 72 | 101.908 | 53.036 | -129.798 | -146.135 | -69.521 | -70.899 | -171.882 | -280.814 | -182.935 | -169.28 |
| Income Before Tax
| 4,218 | 5,076 | 6,720 | 5,873.906 | 5,595.151 | 4,618.814 | 4,263.065 | 3,885.202 | 3,426.05 | 3,372.837 | 2,869.417 | 2,607.988 | 2,454.684 | 1,678.053 | 1,267.996 | 1,169.211 |
| Income Before Tax Ratio
| 0.09 | 0.113 | 0.155 | 0.121 | 0.124 | 0.112 | 0.107 | 0.102 | 0.094 | 0.099 | 0.092 | 0.09 | 0.09 | 0.067 | 0.056 | 0.054 |
| Income Tax Expense
| 1,040 | 1,549 | 2,092 | 1,716.873 | 1,670.41 | 1,122.365 | 1,250.615 | 1,258.186 | 878.698 | 1,136.421 | 1,064.725 | 821.863 | 1,065.543 | 687.433 | 515.61 | 476.246 |
| Net Income
| 3,295 | 3,600 | 4,668 | 4,246 | 3,944.714 | 3,513.028 | 3,041.941 | 2,656.281 | 2,566.419 | 2,246.122 | 1,811.396 | 1,786.636 | 1,389.14 | 990.619 | 752.385 | 692.964 |
| Net Income Ratio
| 0.07 | 0.08 | 0.107 | 0.087 | 0.088 | 0.085 | 0.076 | 0.07 | 0.071 | 0.066 | 0.058 | 0.062 | 0.051 | 0.039 | 0.033 | 0.032 |
| EPS
| 209.99 | 227.64 | 304.9 | 282.75 | 281.51 | 255.23 | 243.1 | 212.26 | 205.07 | 183.51 | 166.58 | 176.48 | 141 | 100.55 | 91.15 | 105.06 |
| EPS Diluted
| 209.99 | 227.45 | 304.9 | 282.75 | 279.51 | 255.23 | 243.1 | 212.26 | 205.07 | 183.51 | 166.58 | 176.48 | 141 | 100.55 | 91.15 | 105.06 |
| EBITDA
| 7,553 | 9,046 | 9,981 | 9,222.277 | 8,419.815 | 7,514.376 | 7,113.105 | 6,676.513 | 6,396.477 | 5,950.863 | 5,441.298 | 5,218.634 | 4,999.644 | 4,155.818 | 3,444.402 | 3,143.291 |
| EBITDA Ratio
| 0.161 | 0.201 | 0.23 | 0.189 | 0.187 | 0.183 | 0.178 | 0.176 | 0.176 | 0.175 | 0.174 | 0.18 | 0.184 | 0.165 | 0.152 | 0.146 |